We are delighted to announce that QEL-001, Quell Tx’s multi-modular engineered CAR-Treg cell therapy, is being advanced into the efficacy cohort of the LIBERATE Phase 1/2 trial in liver transplant patients. A trial progress update was presented today at the American Transplant Congress in Philadelphia, PA, USA. We look forward to entering the next phase of this clinical trial, which has been designed to test a new, potentially transformational paradigm for liver transplant patients. Find out more: https://lnkd.in/ekQeuEy4 #Immunosuppression #Hepatology #ATC2024
This is amazing news, super proud of you all and miss you all
Congratulations to your progress.
Amazing work Quell Therapeutics looking forward to the next updates
Congrats to the whole Quell Team-and best wishes for a successful next step of the trial-patients are waiting!!
Excellent news 👏👏👏👏
Fascinating progress! #CAR-Treg for liver transplant is a gamechanger.
Fantastic news for you all so pleased.
Congratulations to you all, this is great news !
Great work and achievement
Congratulations to the Quell Tx team on advancing QEL-001 into the efficacy cohort of the LIBERATE Phase 1/2 trial! This progress marks a significant step forward in developing innovative CAR-Treg cell therapy for liver transplant patients. Looking forward to seeing the results and the potential impact on the future of transplant medicine.